Arabic Arabic English English French French German German
dark

Cyteir Therapeutics Announces First Patient Dosed in Phase 1 Combination Trial With CYT-0851

Cyteir Therapeutics, Inc. today announced that the first patient has been dosed in a Phase 1 trial evaluating CYT-0851 in combination with three standard-of-care chemotherapy regimens in both hematologic malignancies and solid tumors. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Conference Call on Report on Operations 2021

Next Post

Perceval: CORCYM Announces the First Patient Implanted in China

Related Posts
Total
0
Share